BIOSPECIMENS: The Source of Biomarkers Carolyn Compton, MD, PhD National Biomarkers Development Alliance Public Forum Arizona State University March 25,

Slides:



Advertisements
Similar presentations
Understanding Genome-Wide Profiling of Cancer
Advertisements

The Veterans Affairs Central Biorepository and MVP Highlights Mary T
EUROCHIP PILOT STUDIES. Collection of detailed clinical information for specific tumours Describing and comparing care in representative samples of cancer.
Transforming Correlative Science to Predictive Personalized Medicine Richard Simon, D.Sc. National Cancer Institute
Clinical Trial Designs for the Evaluation of Prognostic & Predictive Classifiers Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer.
EU RTD + FP Cancer Treatment: A priority for patients in Europe 7 th European Health Forum Bad Gastein 7 October, 2004 Cornelius Schmaltz MD European.
 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Biomarkers in Cancer (MBiC) slide presentation is not an independent.
Michael Birrer, PI, Director, Gynecologic Medical Oncology, MGH Lari Wenzel, Co-PI, Prof. of Medicine, University of California, Irvine
MiRNA-drug resistance mechanisms Summary Hypothesis: The interplay between miRNAs, signaling pathways and epigenetic and genetic alterations are responsible.
Biospecimens Carolyn Compton, MD, PhD James Robb, MD Office of Biorepositories and Biospecimen Research (OBBR), NCI June 25, 2007.
CORE COMPETENCIES IN CLINICAL & TRANSLATIONAL RESEARCH: The Child Health Perspective I. Clinical & Translational Research Questions: Extract information.
Gene therapy. Lecture Plan 1.Molecular Medicine and Gene Therapy: An Introduction 2.Vectors in Gene Therapy 1.Viral vector of gene therapy 2.Non viral.
Geonomics in Breast Cancer Decoding Human Genome Luis Barreras, M.D., FACP.
Experimental Design and Biospecimens David F. Ransohoff, MD Division of Gastroenterology and Hepatology; Dept. of Medicine.
Metastatic Breast Cancer: One Size Does Not Fit All Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service MSKCC.
Luděk Bláha, PřF MU, RECETOX BIOMARKERS AND TOXICITY MECHANISMS 13 – BIOMARKERS Summary and final notes.
2nd Quebec Conference on Therapeutic Resistance in Cancer Bienvenue !!!!!
Biorepository Software Selection University of Michigan 31-Aug-2012 Frank Manion, Chief Information Officer Paul McGhee, Lead Business Analyst Cancer Center.
The use of human biospecimens in cancer research Christopher A. Moskaluk M.D., Ph.D. University of Virginia.
Tissue Bank Challenges Repository and Pathologist View Elizabeth H. Hammond M.D.
December 2006 MAGE and the Biospecimen Research Database Experiment Design and other issues Ian Fore, D.Phil U.S. National Cancer Institute - Center for.
ACRIN BDMC Fall 2011 Biostatistics and Data Management Center Constantine Gatsonis, PhD Department of Biostatistics Center for Statistical Sciences Brown.
CORPORATE INNOVATION AS AN ENGINE FOR CHANGE: Molecular Diagnostics David Okrongly, Ph.D. SVP Molecular Diagnostics Siemens Healthcare.
EDRN Approaches to Biomarker Validation DMCC Statisticians Fred Hutchinson Cancer Research Center Margaret Pepe Ziding Feng, Mark Thornquist, Yingye Zheng,
Anticipated FY2016 Appropriations Agency$ Million NIH200 Cancer70 Cohort130 FDA10 Office of the Natl Coord. for Health IT (ONC) 5 TOTAL215 Mission: To.
Precision Medicine A New Initiative. The Concept of Precision Medicine (PM) The prevention and treatment strategies that take individual variability into.
1 Jack London, PhD Research Professor, Cancer Biology Thomas Jefferson University Informatics Shared Resource Director Sidney Kimmel Cancer Center at Jefferson.
100k Genomes Project In December 2012 the Prime Minister announced a programme of Whole Genome Sequencing as part of the UK Government’s Life Sciences.
Biobanking and data sharing for the progress of collaboration on GSD International meeting Glycogen Storage Diseases associations Milan October 2 nd 2010.
The Value of Tissue Banks to Drug and Dx Developers Barbara L. Handelin, Ph.D. Conflicts of Interest, Privacy/Confidentiality, and Tissue Repositories:
April 2005 How Patients Can Benefit From Molecular Imaging Paula M. Jacobs, Ph.D Vice President Advanced Magnetics, Inc.
Sage / DREAM Breast Cancer Prognosis Challenge The goal of the breast cancer prognosis challenge is to assess the accuracy of computational models designed.
GENOMIC RESEARCH: INFORMED CONSENT. Genomics- a branch of genetics that sequences DNA to analyze the structure and function of genomes (the complete set.
NCCCP Biospecimens (BIOSPEC) Breakout Session Carolyn Compton, MD, PhD James Robb, MD Office of Biorepositories and Biospecimen Research (OBBR), NCI June.
1 Establishing an In Vitro Diagnostic (IVD) Claim Robert L. Becker, Jr, MD, PHD Director, Division of Immunology and Hematology Devices OIVD/CDRH/FDA.
Prognostic Value of Genomic Analysis After Neoadjuvant Chemotherapy for Breast Cancer Mayer EL et al. Proc SABCS 2010;Abstract P
Cancers of the Digestive System November 19, 2007 NCDD Meeting Chair: John M. Carethers, MD Vice Chair: Robert Sandler, MD, MPH.
100k Genomes Project Programme of Whole Genome Sequencing, part of UK Life Sciences Strategy Aim to sequence 100,000 genomes from patients with cancer.
Clinical Research and Outcomes Registry Workshop Creating an Informed Consent Form Daniel Ford, MD, MPH Joseph Carrese, MD.
NCCCP Biospecimens (BIOSPEC) Breakout Session Carolyn Compton, MD, PhD James Robb, MD Office of Biorepositories and Biospecimen Research (OBBR), NCI June.
Cancer 101: A Cancer Education and Training Program for American Indians & Alaska Natives Cancer 101: A Cancer Education and Training Program for American.
Rupert R. Horoupian M.D. Steven A. Stanten M.D..
Elena Klenova CTCF and BORIS in normal development, epigenetics and tumourigenesis Areas of research: Molecular Oncology Gene regulation Translational.
NCI Division of Cancer Prevention Ongoing Activities at Frederick Facilities Presented By: Lori Minasian, M.D. Robert Shoemaker, Ph.D. October 1, 2015.
Design and Multiseries Validation of a Web-Based Gene Expression Assay for Predicting Breast Cancer Recurrence and Patient Survival Ryan K. Van Laar The.
The Bridge from Patient to Scientist Comparison: BioBank and Cancer Registry Data Source Distinct Patients Percent BioBank % Cancer Registry %
Duke Index of Biospecimens to Enable Sharing of Biospecimen Collections Abstract The Duke Biobank created the Index of Biospecimens (the Index) to promote.
European Patients’ Academy on Therapeutic Innovation Challenges in Personalised Medicine.
New research areas in personalised medicines
Tissue Collection & Banking Facility
NISCHR Academic Health Science Collaboration Launch
Patient Biospecimen Preanalytics:
NATIONAL outreach Network
Yale SPORE in Skin Cancer
سرطان الثدي Breast Cancer
Mitchell Schnall MD, PhD
100,000 Genomes Project & Mainstreaming Genomic Medicine
Establishment of the National Biorepository in Uganda: Some Regulatory and Ethical Uncertainties Hellen Nansumba, Isaac Ssewanyana and Charles Kiyaga Central.
Clinical applications of CTC and ctDNA analyses in cancer care.
NRG Oncology Biospecimen Bank Report NRG Semiannual meeting
Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E
Raymond N. DuBois, M.D., Ph.D. Executive Director
János Fekete, Balázs Győrffy
Saturation analysis and the discovery of actionability of mutational hotspots. Saturation analysis and the discovery of actionability of mutational hotspots.
One potential implementation for the use of outlier kinase profiling and targeting for clinical management of pancreatic cancer in a precision medicine.
Power THE FUTURE OF FIGHTING CANCER
UAB Tissue Biorepository
Presentation transcript:

BIOSPECIMENS: The Source of Biomarkers Carolyn Compton, MD, PhD National Biomarkers Development Alliance Public Forum Arizona State University March 25, 2013

NBDA BIOSPECIMENS Biospecimen Analysis Biospecimen Collection Biospecimen processing and banking Molecular Data Biomarkers PERSONALIZED/PRECISION MEDICINE Biospecimen Processing, Banking, Data Capture QUALITY HERE DETERMINES QUALITY HERE

IMPACT OF POOR QUALTY BIOSPECIMENS ON BIOMARKERS  Irreproducible research results  Variations in gene expression data  Variations in post-translational modification data  Misinterpretation of artifacts as biomarkers  Potential for incorrect diagnosis  Morphological/immunostaining artifact  Skewed clinical chemistry results  Potential for incorrect treatment  Therapy linked to a diagnostic test on a biospecimen (e.g., HER2 in breast cancer)

NDBA BIOSPECIMENS AND BIOBANK  Poor quality biospecimens + High quality biorepository  High quality biospecimens + Low quality biorepository  High quality biospecimens +  High quality biorepository  NDBA   The right samples from the right patients at the right time  Evidence-based collection, processing, storage protocols  Quality verification at every step, every time  Rich, diverse data on every sample  Best specimen type for the intended assay “Fit for purpose” Purpose defined by analysis method for the target biomolecule type and the intended use of the analysis data

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.